Overview
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Eligibility
Inclusion Criteria:
- Patients >18 year old admitted for allo SCT PB for malignant disease.